MiR-650 represses high-risk non-metastatic colorectal cancer progression via inhibition of AKT2/GSK3β/E-cadherin pathway

Chunxian Zhou; Fengyun Cui; Jiali Li; Diyi Wang; Yingze Wei; Ying Wu; Jiping Wang; Hongguang Zhu; Shuyang Wang

doi:10.18632/oncotarget.17743

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

MiR-650 represses high-risk non-metastatic colorectal cancer progression via inhibition of AKT2/GSK3β/E-cadherin pathway

Chunxian Zhou, Fengyun Cui, Jiali Li, Diyi Wang, Yingze Wei, Ying Wu, Jiping Wang, Hongguang Zhu and Shuyang Wang _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:49534-49547. https://doi.org/10.18632/oncotarget.17743

Metrics: PDF 1988 views | HTML 2221 views | ?

Abstract

Chunxian Zhou1,2,*, Fengyun Cui1,*, Jiali Li1,*, Diyi Wang1, Yingze Wei1, Ying Wu1,#, Jiping Wang3, Hongguang Zhu1 and Shuyang Wang1

1Department of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai, China

2Department of Pathology, Shanghai University of Traditional Chinese Medicine, Shanghai, China

3Division of Surgical Oncology, Brigham and Women Medicine, Harvard Medical School, Boston, Massachusetts, USA

#Dedication: We would like to dedicate this paper to Professor Ying Wu, who unfortunately passed away in 2015. Professor Ying Wu played an essential role in this study and she is greatly missed

*These authors contributed equally to this work

Correspondence to:

Shuyang Wang, email: [email protected]

Hongguang Zhu, email: [email protected]

Keywords: non-metastatic colorectal cancer, prognosis biomarker, microRNA, AKT pathway

Received: October 12, 2016 Accepted: April 24, 2017 Published: May 10, 2017

ABSTRACT

Although 5-year survival rate of non-metastatic colorectal cancer (CRC) is high, about 10% of patients in stage I and II still develop into metastatic CRC and eventually die after resection. Currently, there is no effective biomarker for predicting the prognosis of non-metastatic CRC in clinical practice. In this study, we identified miR-650 as a biomarker for prognosis prediction. We observed that the expression of miR-650 in tumor tissues had a positive association with overall survival. MiR-650 inhibited cell growth and invasion in vitro and in vivo. Furthermore, miR-650 targeted AKT2 and repressed the activation of the AKT pathway (AKT2/GSK3β/E-cadherin). Thus it induced the translocation of E-cadherin and β-catenin in cancer cells. Our results highlight the potential of miR-650 as a prognostic prediction biomarker and therapeutic target in non-metastatic CRC via inhibition of the AKT2/GSK3β/E-cadherin pathway.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17743

Publication Alerts

Research Papers:

MiR-650 represses high-risk non-metastatic colorectal cancer progression via inhibition of AKT2/GSK3β/E-cadherin pathway

Abstract